FDA Warns Prolia May Cause Severe Low Blood Calcium Levels
The FDA began investigating a link between side effects of Prolia and hypocalcemia in November 2022, following adverse reports from dialysis patients.
Tag Archives: Amgen
-
-
FTC to Allow Tepezza Manufacturer to be Bought By Amgen Amid Growing Hearing Loss Litigation
The deal seeks to prevent Amgen from leveraging its near-monopoly on Tepezza and other Horizon drugs into an overwhelming competitive advantage.
-
FTC Files Lawsuit To Prevent Amgen From Acquiring Manufacturer of Tepezza, Krystexxa
Acquiring Tepezza and Krystexxa would give Amgen a monopoly on those treatments, which it could then use to smother competition, the FTC warns
-
Investors File Lawsuit To Prevent Acquisition of Tepezza Manufacturer Horizon Therapeutics
Plaintiffs say Horizon has failed to share key financial projections to shareholders of what will likely happen if Amgen buys Tepezza manufacturer Horizon Therapeutics
-
Horizon Therapeutics Acquired for Nearly $30B Amid Growing Threat of Tepezza Lawsuit Payouts
Amgen agreed to buy Horizon as it faces unknown liability from Tepezza lawsuits over hearing loss suffered by users of the thyroid eye disease drug
-
Prolia Hypocalcemia Problems Among Dialysis Patients Results in FDA Investigation
Prolia side effects may increase the risk of dangerously low calcium levels in the blood of individuals undergoing dialysis treatment, according to interim findings of an ongoing study
-
Woman Suffers Multiple Vertebral Fractures After Stopping Prolia: Case Report
The findings support previous studies which have linked Prolia discontinuation to an increased risk in bone fractures, though this is one of the first cases detected in a bone cancer patient.
-
Prolia Discontinuation Increases The Risk Of Vertebral Fractures, Study Found
-
Prolia Fracture Risk Leads Public Citizen to Call For Black Box Warning
-
Kyprolis Side Effects May Increase Risks of Heart Problems, Researchers Warn
